<?xml version="1.0" encoding="UTF-8"?>
<ref id="B14">
 <label>14.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ng</surname>
    <given-names>SC</given-names>
   </name>
   <name>
    <surname>Hilmi</surname>
    <given-names>IN</given-names>
   </name>
   <name>
    <surname>Blake</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Bhayat</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Adsul</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Khan</surname>
    <given-names>QR</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting</article-title>. 
  <source>Inflamm Bowel Dis.</source> (
  <year>2018</year>) 
  <volume>24</volume>:
  <fpage>2431</fpage>â€“
  <lpage>41</lpage>. 
  <pub-id pub-id-type="doi">10.1093/ibd/izy153</pub-id>
  <?supplied-pmid 30312414?>
  <pub-id pub-id-type="pmid">30312414</pub-id>
 </mixed-citation>
</ref>
